Publication

Endothelial progenitor cell-based neovascularization: implications for therapy

Krenning, G., van Luyn, M. J. A. & Harmsen, M. C., Apr-2009, In : TRENDS IN MOLECULAR MEDICINE. 15, 4, p. 180-189 10 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Krenning, G., van Luyn, M. J. A., & Harmsen, M. C. (2009). Endothelial progenitor cell-based neovascularization: implications for therapy. TRENDS IN MOLECULAR MEDICINE, 15(4), 180-189. https://doi.org/10.1016/j.molmed.2009.02.001

Author

Krenning, Guido ; van Luyn, Marja J. A. ; Harmsen, Martin C. / Endothelial progenitor cell-based neovascularization : implications for therapy. In: TRENDS IN MOLECULAR MEDICINE. 2009 ; Vol. 15, No. 4. pp. 180-189.

Harvard

Krenning, G, van Luyn, MJA & Harmsen, MC 2009, 'Endothelial progenitor cell-based neovascularization: implications for therapy', TRENDS IN MOLECULAR MEDICINE, vol. 15, no. 4, pp. 180-189. https://doi.org/10.1016/j.molmed.2009.02.001

Standard

Endothelial progenitor cell-based neovascularization : implications for therapy. / Krenning, Guido; van Luyn, Marja J. A.; Harmsen, Martin C.

In: TRENDS IN MOLECULAR MEDICINE, Vol. 15, No. 4, 04.2009, p. 180-189.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Krenning G, van Luyn MJA, Harmsen MC. Endothelial progenitor cell-based neovascularization: implications for therapy. TRENDS IN MOLECULAR MEDICINE. 2009 Apr;15(4):180-189. https://doi.org/10.1016/j.molmed.2009.02.001


BibTeX

@article{27952bb4ae5b4ff68c74944fbbf2f15d,
title = "Endothelial progenitor cell-based neovascularization: implications for therapy",
abstract = "Ischemic cardiovascular events are a major cause of death globally. Endothelial progenitor cell (EPC)-based approaches can result in improvement of vascular perfusion and might offer clinical benefit. However, although functional improvement is observed, the lack of long-term engraftment of EPCs into neovessels has raised controversy regarding their mechanism of action. We and others have hypothesized that after ischemic injury, EPCs induce neovascularization through the secretion of cytokines and growth factors, which act in a paracrine fashion and induce sprouting angiogenesis by the surrounding endothelium. In this concise review, we discuss the (patho)physiology of EPC-induced neovascularization and focus on the paracrine signals secreted by EPCs and the effects they elicit. In future therapies, clinical administration of these paracrine modulators using slow-release depots might induce neovascularization and might therefore hold promise for vascular regenerative medicine.",
keywords = "ACUTE MYOCARDIAL-INFARCTION, UMBILICAL-CORD BLOOD, BONE-MARROW-CELLS, HUMAN CD34(+) CELLS, RANDOMIZED CONTROLLED-TRIAL, GROWTH-FACTOR DELIVERY, REPAIR-AMI TRIAL, IN-VITRO CULTURE, STEM-CELLS, POSTNATAL NEOVASCULARIZATION",
author = "Guido Krenning and {van Luyn}, {Marja J. A.} and Harmsen, {Martin C.}",
year = "2009",
month = "4",
doi = "10.1016/j.molmed.2009.02.001",
language = "English",
volume = "15",
pages = "180--189",
journal = "TRENDS IN MOLECULAR MEDICINE",
issn = "1471-4914",
publisher = "ELSEVIER SCI LTD",
number = "4",

}

RIS

TY - JOUR

T1 - Endothelial progenitor cell-based neovascularization

T2 - implications for therapy

AU - Krenning, Guido

AU - van Luyn, Marja J. A.

AU - Harmsen, Martin C.

PY - 2009/4

Y1 - 2009/4

N2 - Ischemic cardiovascular events are a major cause of death globally. Endothelial progenitor cell (EPC)-based approaches can result in improvement of vascular perfusion and might offer clinical benefit. However, although functional improvement is observed, the lack of long-term engraftment of EPCs into neovessels has raised controversy regarding their mechanism of action. We and others have hypothesized that after ischemic injury, EPCs induce neovascularization through the secretion of cytokines and growth factors, which act in a paracrine fashion and induce sprouting angiogenesis by the surrounding endothelium. In this concise review, we discuss the (patho)physiology of EPC-induced neovascularization and focus on the paracrine signals secreted by EPCs and the effects they elicit. In future therapies, clinical administration of these paracrine modulators using slow-release depots might induce neovascularization and might therefore hold promise for vascular regenerative medicine.

AB - Ischemic cardiovascular events are a major cause of death globally. Endothelial progenitor cell (EPC)-based approaches can result in improvement of vascular perfusion and might offer clinical benefit. However, although functional improvement is observed, the lack of long-term engraftment of EPCs into neovessels has raised controversy regarding their mechanism of action. We and others have hypothesized that after ischemic injury, EPCs induce neovascularization through the secretion of cytokines and growth factors, which act in a paracrine fashion and induce sprouting angiogenesis by the surrounding endothelium. In this concise review, we discuss the (patho)physiology of EPC-induced neovascularization and focus on the paracrine signals secreted by EPCs and the effects they elicit. In future therapies, clinical administration of these paracrine modulators using slow-release depots might induce neovascularization and might therefore hold promise for vascular regenerative medicine.

KW - ACUTE MYOCARDIAL-INFARCTION

KW - UMBILICAL-CORD BLOOD

KW - BONE-MARROW-CELLS

KW - HUMAN CD34(+) CELLS

KW - RANDOMIZED CONTROLLED-TRIAL

KW - GROWTH-FACTOR DELIVERY

KW - REPAIR-AMI TRIAL

KW - IN-VITRO CULTURE

KW - STEM-CELLS

KW - POSTNATAL NEOVASCULARIZATION

U2 - 10.1016/j.molmed.2009.02.001

DO - 10.1016/j.molmed.2009.02.001

M3 - Review article

VL - 15

SP - 180

EP - 189

JO - TRENDS IN MOLECULAR MEDICINE

JF - TRENDS IN MOLECULAR MEDICINE

SN - 1471-4914

IS - 4

ER -

ID: 4892813